JP2020019813A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020019813A5 JP2020019813A5 JP2019186857A JP2019186857A JP2020019813A5 JP 2020019813 A5 JP2020019813 A5 JP 2020019813A5 JP 2019186857 A JP2019186857 A JP 2019186857A JP 2019186857 A JP2019186857 A JP 2019186857A JP 2020019813 A5 JP2020019813 A5 JP 2020019813A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- amino acid
- composition
- syndrome
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 6
- 102100022002 CD59 glycoprotein Human genes 0.000 claims 5
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims 4
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 2
- 102100039373 Membrane cofactor protein Human genes 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000007475 hemolytic anemia Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 206010036303 Post streptococcal glomerulonephritis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 201000005638 acute proliferative glomerulonephritis Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 208000022401 dense deposit disease Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000003974 emollient agent Substances 0.000 claims 1
- 231100000562 fetal loss Toxicity 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 102000051442 human CD59 Human genes 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 208000017262 paroxysmal cold hemoglobinuria Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 231100000760 phototoxic Toxicity 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043084P | 2014-08-28 | 2014-08-28 | |
| US62/043,084 | 2014-08-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511190A Division JP6651506B2 (ja) | 2014-08-28 | 2015-08-28 | 補体関連障害を処置するための組成物、方法およびキット |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020207487A Division JP7275095B2 (ja) | 2014-08-28 | 2020-12-15 | 補体関連障害を処置するための組成物、方法およびキット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020019813A JP2020019813A (ja) | 2020-02-06 |
| JP2020019813A5 true JP2020019813A5 (enExample) | 2020-03-19 |
| JP6811821B2 JP6811821B2 (ja) | 2021-01-13 |
Family
ID=55400647
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511190A Active JP6651506B2 (ja) | 2014-08-28 | 2015-08-28 | 補体関連障害を処置するための組成物、方法およびキット |
| JP2019186857A Active JP6811821B2 (ja) | 2014-08-28 | 2019-10-10 | 補体関連障害を処置するための組成物、方法およびキット |
| JP2020207487A Active JP7275095B2 (ja) | 2014-08-28 | 2020-12-15 | 補体関連障害を処置するための組成物、方法およびキット |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511190A Active JP6651506B2 (ja) | 2014-08-28 | 2015-08-28 | 補体関連障害を処置するための組成物、方法およびキット |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020207487A Active JP7275095B2 (ja) | 2014-08-28 | 2020-12-15 | 補体関連障害を処置するための組成物、方法およびキット |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10813977B2 (enExample) |
| EP (2) | EP3892291A1 (enExample) |
| JP (3) | JP6651506B2 (enExample) |
| AU (1) | AU2015308773B2 (enExample) |
| ES (1) | ES2872537T3 (enExample) |
| WO (1) | WO2016033444A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2843684A1 (en) * | 2010-08-13 | 2012-02-16 | Tufts University | Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein |
| JP6651506B2 (ja) | 2014-08-28 | 2020-02-19 | タフツ・ユニバーシティ | 補体関連障害を処置するための組成物、方法およびキット |
| GB201608046D0 (en) * | 2016-05-09 | 2016-06-22 | Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The | Treatment of complement-mediated disorders |
| US20200138966A1 (en) * | 2017-01-27 | 2020-05-07 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Bifunctional small peptide for autoimmune diabetes |
| CN109331186B (zh) * | 2018-10-10 | 2022-04-05 | 华南师范大学 | 一种脂质体修饰的金纳米粒复合物及其在治疗帕金森氏症方面的应用 |
| KR20210151918A (ko) * | 2019-04-13 | 2021-12-14 | 내쇼날 센터 포 셀 사이언시즈 | Daf-mcp 키메라 단백질, 이의 제조 방법 및 보체계 관련 병리학적 상태 치료를 위한 상기 키메라 단백질의 용도 |
| US20240279680A1 (en) * | 2021-06-18 | 2024-08-22 | Ikarovec Limited | Retinal Disorders |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4405712A (en) | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| WO1985005629A1 (en) | 1984-05-25 | 1985-12-19 | Dana-Farber Cancer Institute | Ltr vectors, methods of preparation and use |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
| WO1989007150A1 (en) | 1988-02-05 | 1989-08-10 | The Trustees Of Columbia University In The City Of | Retroviral packaging cell lines and processes of using same |
| US5112767A (en) | 1988-03-04 | 1992-05-12 | University Of Southern California | Vectors with enhancer domains |
| JP3082204B2 (ja) | 1988-09-01 | 2000-08-28 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス |
| WO1990002797A1 (en) | 1988-09-15 | 1990-03-22 | North Carolina State University | Self-inactivating, replication defective, retroviral vectors and helper cells for producing the same |
| US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
| WO1990013641A1 (en) | 1989-05-10 | 1990-11-15 | Sloan-Kettering Institute For Cancer Research | Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter |
| WO1992005266A2 (en) | 1990-09-21 | 1992-04-02 | Viagene, Inc. | Packaging cells |
| WO1992007573A1 (en) | 1990-10-31 | 1992-05-14 | Somatix Therapy Corporation | Genetic modification of endothelial cells |
| US5122767A (en) | 1991-01-10 | 1992-06-16 | Northern Telecom Limited | Saw device tapped delay lines |
| EP0572401B2 (en) | 1991-02-19 | 2007-11-07 | The Regents of the University of California | Viral particles having altered host range |
| AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
| US5627264A (en) | 1994-03-03 | 1997-05-06 | Alexion Pharmaceuticals, Inc. | Chimeric complement inhibitor proteins |
| US5851826A (en) | 1995-07-26 | 1998-12-22 | Children's Medical Center Corporation | Helper virus-free herpesvirus vector packaging system |
| US5843884A (en) | 1995-11-15 | 1998-12-01 | Oklahoma Medical Research Foundation | C9 complement inhibitor |
| US7166568B1 (en) | 1998-02-09 | 2007-01-23 | Oklahoma Medical Research Foundation | Compositions and methods to inhibit formation of the C5b-9 complex of complement |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| WO2009102488A2 (en) | 2008-02-15 | 2009-08-20 | Tufts University | A humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration |
| WO2012016162A2 (en) * | 2010-07-29 | 2012-02-02 | Tufts University | Compositions, methods and kits for modeling, diagnosing, and treating complement disorders |
| US8877896B2 (en) * | 2008-02-15 | 2014-11-04 | Tufts University | Compositions, methods and kits for modeling, diagnosing, and treating complement disorders |
| AU2014209350B8 (en) * | 2013-01-23 | 2019-04-18 | Department Of Veterans Affairs (Us) | Targeting constructs based on natural antibodies and uses thereof |
| US9617940B2 (en) | 2014-08-14 | 2017-04-11 | General Electric Company | Engine diagnostic system and an associated method thereof |
| JP6651506B2 (ja) | 2014-08-28 | 2020-02-19 | タフツ・ユニバーシティ | 補体関連障害を処置するための組成物、方法およびキット |
-
2015
- 2015-08-28 JP JP2017511190A patent/JP6651506B2/ja active Active
- 2015-08-28 ES ES15836880T patent/ES2872537T3/es active Active
- 2015-08-28 EP EP21161633.9A patent/EP3892291A1/en active Pending
- 2015-08-28 EP EP15836880.3A patent/EP3186269B1/en active Active
- 2015-08-28 WO PCT/US2015/047405 patent/WO2016033444A1/en not_active Ceased
- 2015-08-28 AU AU2015308773A patent/AU2015308773B2/en active Active
-
2017
- 2017-02-28 US US15/444,500 patent/US10813977B2/en active Active
-
2019
- 2019-10-10 JP JP2019186857A patent/JP6811821B2/ja active Active
-
2020
- 2020-10-09 US US17/067,515 patent/US11654179B2/en active Active
- 2020-12-15 JP JP2020207487A patent/JP7275095B2/ja active Active
-
2023
- 2023-05-19 US US18/199,616 patent/US20230414714A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020019813A5 (enExample) | ||
| CN111217918B (zh) | 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗 | |
| JP6811821B2 (ja) | 補体関連障害を処置するための組成物、方法およびキット | |
| JP2017527558A5 (enExample) | ||
| CN108350462B (zh) | 嵌合抗原受体及其用途 | |
| JP2015505299A5 (enExample) | ||
| CN113173995B (zh) | 一种结合冠状病毒的双特异性抗体 | |
| CN113527510A (zh) | 融合蛋白分子及其制备方法和用途 | |
| JP2008508885A5 (enExample) | ||
| JP2000516098A (ja) | 短シャフトアデノウイルスファイバーおよびその用途 | |
| JP2017537888A5 (enExample) | ||
| CN112194726B (zh) | 用于病理性蛋白聚集物清除的嵌合抗原受体及其应用 | |
| WO2017059819A1 (zh) | 高亲和力的可溶性pdl-1分子 | |
| US20220348954A1 (en) | Targeted exosome based on rbd region of sars-cov-2 s protein and preparation method thereof | |
| CN114081965B (zh) | 一种外泌体递送载体及其制备方法、应用 | |
| JP4080423B2 (ja) | アデノウイルスタンパク質ｉｘ、ならびにキャプシドアセンブリー、転写活性および核再組織化に関与するそのドメイン | |
| CN107880117A (zh) | 识别人乙型肝炎病毒x蛋白的单克隆抗体及用途 | |
| WO2023179548A1 (zh) | 纳米抗体s43的构建体及其应用 | |
| US8932601B2 (en) | Hybrid and chimeric polypeptides that regulate activation of complement | |
| CN107502612A (zh) | 一种识别结合WSSV的层粘连蛋白受体基因Cq‑LR及其制备方法与应用 | |
| WO2021174567A1 (zh) | 一种基于细菌复合物的新型冠状病毒s蛋白双区域亚单位纳米疫苗 | |
| TWI508973B (zh) | 親和力成熟之ＣＲＩｇ變體 | |
| JPWO2020027010A5 (enExample) | ||
| WO2016165301A1 (zh) | MUC1-Fc多肽疫苗及其制备方法和应用 | |
| CN109897107A (zh) | 纳米抗体及其制备方法 |